NCT06803875View on ClinicalTrials.gov

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-risk Neuroblastoma
Interventions
BIOLOGICAL

Autologous hALK.CAR T cells

Autologous chimeric antigen receptor T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor

Trial Locations (2)

02115

RECRUITING

Boston Children's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Boston Children's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Roberto Chiarle

OTHER